THAR Stock Risk & Deep Value Analysis
THAR
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About THAR Stock
We analyzed THAR using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran THAR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is THAR Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for THAR?
- ⚠
Phase 2 clinical trial delays or higher than expected patient dropout rates
- ⚠
Need for additional dilutive capital raises to fund operations
- ⚠
Negative results from preclinical or early-stage clinical work
Unlock THAR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does THAR (THAR) Do?
Market Cap
$24.35M
Sector
Healthcare
Industry
Biotechnology
Employees
2
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Visit THAR WebsiteIs THAR Stock Undervalued?
Unlock the full AI analysis for THAR
Get the complete DVR score, risk analysis, and more
Does THAR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat is primarily driven by intellectual property surrounding TH104. Its durability will depend on the strength and breadth of patents, and ultimately, on the successful clinical development and market approval of TH104. Without clinical validation, the IP has limited commercial value.
Moat Erosion Risks
- •Clinical trial failure or significant delays
- •Competitive drugs with superior efficacy or safety profiles emerging
- •Patent challenges or expiration
THAR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive THAR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late May 2026)
- •Updates on TH104 Phase 2 patient enrollment progress
Medium-Term (6-18 months)
- •Potential pre-clinical data for additional indications of TH104
- •Strategic partnership or licensing deal announcements (unlikely but possible before Phase 2 completion)
- •Interim data readout for TH104 Phase 2 trial (late 2026 / early 2027 possibility)
Long-Term (18+ months)
- •Full Phase 2 data readout for TH104 in Prurigo Nodularis (2027)
- •Initiation of Phase 3 clinical trials for TH104
- •Potential FDA approval of TH104
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for THAR?
- ✓
Positive updates on TH104 Phase 2 enrollment and progress
- ✓
Announcement of non-dilutive financing or strategic collaboration
- ✓
Significant changes in cash burn rate or cash runway
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for THAR (THAR) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
